Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis

Inclusion criteria: * Patients with rheumatoid arthritis (RA) as defined by the American College of Rheumatology (ACR)/European League against Rheumatism (EULAR) 2010 * Rheumatoid Arthritis Classification Criteria. * ACR Class I-III functional status, based on the 1991 revised criteria. Exclusion criteria: * Patients less than 20 years of age. * Prior treatment with any biologic anti-interleukin-6 (anti-IL-6) or interleukin-6 receptor (IL-6R) antagonist. * Any parenteral or intraarticular glucocorticoid injection within 4 weeks prior to randomization. * Treatment with prednisone higher than 10 mg or equivalent per day, or change in dosage within 4 weeks prior to randomization. * Treatment with disease-modifying antirheumatic drugs (DMARDs), immunosuppressive agents, tumor necrosis factor (TNF) antagonists or any other RA-directed biologic agents within a certain amount of time prior to randomization. * Participation in any clinical research study that evaluated an investigational drug or therapy within 5 half-lives or 60 days of the screening visit, whichever is longer. * Active or suspected tuberculosis (TB) or at high risk of contracting TB. * Fever, or chronic, persistent, or recurring infection(s) requiring active treatment. * The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.